## **UNITED STATES**

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 6, 2020

### NEUROMETRIX, INC.

(Exact name of registrant as specified in charter)

Delaware

**001-33351** (Commission File Number) 04-3308180

(IRS Employer Identification No.)

(State or other jurisdiction of incorporation)

4B Gill Street, Woburn, Massachusetts

(Address of principal executive offices)

(781) 890-9989

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

0 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

0 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

0 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

01801

(Zip Code)

#### 0 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                        | Trading Symbol(s) | Name of exchange on which registered |
|--|-------------------|--------------------------------------|
| Common Stock, \$0.0001 par value per share | NURO              | The Nasdaq Stock Market LLC          |
| Preferred Stock Purchase Rights            | NUROW             |                                      |
| Warrants to Purchase Common Stock          |                   |                                      |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

#### Emerging growth company $\Box$

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### Item 8.01. Other Events.

As previously disclosed, on April 28, 2020, NeuroMetrix, Inc. (the "Company") received a loan of \$773,200 (the "Loan") from Comerica Bank (the "Bank") under the U.S. Small Business Administration ("SBA") Paycheck Protection Program (the "PPP") of the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"). The Company planned to use the proceeds from the Loan for covered payroll costs, rent and utilities in accordance with the relevant terms and conditions of the CARES Act.

On May 6, 2020, following the issuance of new guidance from the SBA regarding specific eligibility requirements under the PPP, the Company initiated the immediate repayment of the full amount of the Loan to the Bank.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### NEUROMETRIX, INC.

Date: May 7, 2020 By: <u>/s/ Thomas T. Higgins</u>

Thomas T. Higgins Senior Vice President,

Chief Financial Officer and Treasurer